Results from a matching-adjusted indirect comparison suggest that cabozantinib provides two additional months of progression-free survival versus regorafenib in the second-line treatment.
An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.